Retatrutide
Also known as: LY3437943
Retatrutide (LY3437943) is an investigational synthetic peptide and single-molecule agonist of the GIP, GLP-1, and glucagon receptors. As of July 2026, it remains under clinical investigation and has not been approved by the FDA or any other regulatory agency.
Molecular Properties
Molecular Formula
C237H353N49O74
Molecular Weight
5430.8
CAS Number
2381089-83-2
Research History
Developed by Eli Lilly, retatrutide was evaluated in a peer-reviewed Phase 2 trial published in 2023 and is being studied in Phase 3 TRIUMPH and TRANSCEND programs. Lilly reported additional topline Phase 3 results in 2025 and 2026; regulatory review and approval have not been completed.
Studied Mechanisms
Retatrutide is studied for coordinated agonism at GIP, GLP-1, and glucagon receptors. These receptor systems participate in nutrient-responsive signaling, glucose regulation, lipid metabolism, and energy-balance pathways. Whether combined activity produces distinct safety and efficacy outcomes is a clinical research question and should not be inferred from receptor activity alone.
Storage Reference
-20°C for long term
Handling Reference
Follow lot-specific COA/SDS instructions and standard laboratory peptide handling procedures; avoid unnecessary temperature cycling.